Your session is about to expire
← Back to Search
NFX-179 Gel for Epidermal Nevus
Study Summary
This trial is testing a new topical gel, NFX-179, to see if it is safe and effective in treating a skin condition called epidermal nevus syndrome. The gel is applied once daily for 12 weeks. The primary objective is to determine if the gel suppresses a protein called phospho-ERK in the skin. The secondary objective is to see if the gel reduces the size of epidermal nevi.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I haven't taken any retinoid medications in the last 90 days.You have to be calm and not show signs of irritation.I am currently taking or have taken Fluorouracil.I have used topical MEK or BRAF inhibitors for my condition.My skin condition has been confirmed by a biopsy.I agree not to seek other treatments for my condition outside of the study.I do not have any skin infections.My lesion is isolated with healthy skin around it.I have never had surgery for my condition.I have a history of significant liver problems.I am willing and able to follow the study's requirements and attend all visits.I am a woman who can have children, not pregnant, and willing to use birth control during the study.You are not experiencing any irritation.I have never had surgery for my condition.I haven't taken BRAF inhibitors in the last 6 months.I have had cancer spread or active cancer, except for certain types, in the last 5 years.I am willing to avoid sunlight and artificial UV light.I am currently using or have used Imiquimod.You are allergic to any of the ingredients in the study medications.I haven't taken MEK inhibitors in the last 6 months.I use products with more than 5% alpha-hydroxy acid.I am using steroid creams or ointments.Your measurement is 15 millimeters or longer.My affected area is 100cm2 or smaller.I can reach the area where I need to apply the medication.I am using a cream or gel for my skin condition.I am 18 years old or older.I am willing to not use any non-study skin medications during the trial.I have a specific skin condition targeted for treatment.I have not used specific medications recently.I am willing to avoid sun and artificial UV light exposure.My lesion is isolated with healthy skin around it.
- Group 1: Patients receiving NFX-179 Gel
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Has the NFX-179 Gel 1.50% been approved by the Food and Drug Administration?
"Our evaluation of NFX-179 Gel 1.50%'s safety rate it a 2 out of 3, as this is still in Phase 2 trials and there are some indications that the drug has not been proven efficacious yet."
Is enrollment for this research endeavor still open?
"The details provided on clinicaltrials.gov reveal that this trial is no longer actively recruiting patients; it was initially posted on June 1st 2023, and last edited October 25th 2022. Nevertheless, there are 7 other studies accepting enrollees at the present time."
Who else is applying?
What state do they live in?
What portion of applicants met pre-screening criteria?
How many prior treatments have patients received?
What questions have other patients asked about this trial?
Why did patients apply to this trial?
Share this study with friends
Copy Link
Messenger